Salivary cortisol levels and the 2-year course of depressive and anxiety disorders  by Vreeburg, Sophie A. et al.
Salivary cortisol levels and the 2-year course of
depressive and anxiety disorders
Sophie A. Vreeburg a, Witte J.G. Hoogendijk a,b, Roel H. DeRijk c,
Richard van Dycka, Johannes H. Smit a, Frans G. Zitman c,
Brenda W.J.H. Penninx a,b,c,d,*
aDepartment of Psychiatry, EMGO institute for Health and Care research, VU University Medical Center, Amsterdam,
The Netherlands
bNeuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
cDepartment of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands
dDepartment of Psychiatry, University Medical Center Groningen, Groningen, The Netherlands
Received 1 June 2012; received in revised form 14 December 2012; accepted 19 December 2012
Psychoneuroendocrinology (2013) 38, 1494—1502
KEYWORDS
HPA axis;
Salivary cortisol;
Depressive disorder;
Anxiety disorder;
Course
Summary
Introduction: Depression and anxiety disorders have been associated with hyperactivity of the
hypothalamic-pituitary adrenal (HPA) axis. However, lower cortisol levels have also been
observed in depressed patients. Whether cortisol level predicts the course of these disorders
has not been examined in detail. We examined whether salivary cortisol indicators predict the
2-year course of depression and anxiety disorders.
Methods: Longitudinal data are obtained from 837 participants of the Netherlands Study of
Depression and Anxiety, with a DSM-IV based depressive and/or anxiety disorder at baseline. At
baseline, seven saliva samples were obtained, including the 1-h cortisol awakening response,
evening cortisol level and a 0.5 mg dexamethasone suppression test. At follow-up, DSM-IV based
diagnostic interviews and Life Chart Interview integrating diagnostic and symptom trajectories
over 2 years were administered to determine an unfavorable course.
Results: 41.5% of the respondents had a 2-year unfavorable course trajectory without remission
longer than 3 months. Adjusted analyses showed that a lower awakening response was associated
with an unfavorable course (RR = 0.83, p = 0.03). No associations were found between evening
cortisol or cortisol suppression after dexamethasone ingestion and an unfavorable course
trajectory.
Conclusions: Among patients with depressive or anxiety disorders, a lower cortisol awakening
response — which may be indicative of underlying exhaustion of the HPA axis — predicted an
unfavorable course trajectory.
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Cortisol levels and course of depression and anxiety 14951. Introduction
Depressive and anxiety disorders are prevalent and disabling
disorders. The burden is partly due to their course, often
chronic or recurrent. In addition, comorbidity of depression
and anxiety disorder frequently occurs (Kessler et al., 1996)
and is related to an even poorer outcome (Merikangas et al.,
2003; Penninx et al., 2011). However, little is known about
predictors of the course of these disorders, while such knowl-
edge would greatly improve our understanding of these
diseases or could lead to identification of risk groups.
Hypothalamic-pituitary-adrenal (HPA) axis dysregulation is
believed to play an important role in the pathophysiology of
depressive and — to a lesser extent — anxiety disorders.
Mostly, hyperactivity of the HPA axis has been observed, as
reflected by elevated cortisol levels, in addition to less
suppression of cortisol after a dexamethasone suppression
test (DST) or Dexamethasone/Corticotropin Releasing Hor-
mone (Dex/CRH) test for depression (Modell et al., 1997;
Bhagwagar et al., 2005; Vreeburg et al., 2009a) or panic
disorder (Abelson et al., 2007). However, there also appears
to be a group of patients showing hypocortisolism (Oldehinkel
et al., 2001; Bremmer et al., 2007; Penninx et al., 2007),
possibly a sign of exhaustion of the HPA axis, after chronic and
recurrent depressive episodes (Oldehinkel et al., 2001;
Bremmer et al., 2007). Salivary cortisol measures are
increasingly used, since they reflect unbound, active cortisol,
and their collection is minimally intrusive (Kirschbaum and
Hellhammer, 1989). The cortisol awakening response reflects
the natural response of the HPA axis on awakening (Fries
et al., 2009), which represents a distinct feature of the HPA
axis and has received increasing interest as a promising
biomarker in the previous years (Clow et al., 2010). Evening
levels reflect basal activity, and the DST provides information
on the negative feedback system (Carroll et al., 1981). Using
these measures, we observed that persons with a remitted or
current Major Depressive Disorder (MDD) showed a higher
cortisol awakening curve (Vreeburg et al., 2009a), as did
persons with a current Panic Disorder with agoraphobia
(Vreeburg et al., 2010b). Persons with other anxiety disorders
e.g. social phobia, generalized anxiety disorder and panic
disorder without agoraphobia did not show different cortisol
levels as compared to controls.
Although cross-sectional associations have been estab-
lished, it remains largely unclear whether HPA-axis dysregu-
lation predicts the course of depression and anxiety
disorders. Longitudinal studies investigating such temporal
associations are important, since they learn us more about
the underlying interaction of HPA-axis dysregulation and
depression and anxiety disorders. In addition, they provide
insights into the clinical implications of HPA-axis dysregula-
tion as they may point out whether hypo- and or hyperactivity
of the HPA-axis does identify patients with a more unfavor-
able course trajectory e.g. due to HPA-axis dysregulation
negatively impacting mood recovery processes or limiting
treatment efficacy. There is some evidence that increased
cortisol responses to the Dex/CRH test or DST predict relapse
in remitted outpatients with depressive disorder (Ribeiro
et al., 1993; Appelhof et al., 2006; Aubry et al., 2007; Pintor
et al., 2009), panic disorder (Coryell et al., 1989), or in
depressed inpatients (Zobel et al., 1999; Ising et al.,2007). Baseline salivary cortisol, cortisol responses on the
DST or Dex/CRH test, however, were not related to the
treatment response or outcome of depression or panic dis-
order (Coryell and Noyes, 1988; Ribeiro et al., 1993; Hatzin-
ger et al., 2002; Schule et al., 2003; Brouwer et al., 2006;
Papakostas et al., 2010). However, for panic disorder, abnor-
mal DSTresults (Coryell et al., 1991) or elevated 24-h cortisol
levels (Abelson and Curtis, 1996) were also associated with
more anxiety, phobias and disability 2—4 years later.
Overall, the above described studies do provide some
inconsistent indications that HPA-axis activity may predict
the course trajectory of depression and anxiety disorders.
Several of these studies were rather small-scaled and not
always checked whether the predicting value of HPA-axis
indicators is due to or independent of correlated clinical
characteristics, such as baseline symptom severity. Large-
scale longitudinal studies examining the role of HPA-axis
indicators in the naturalistic course trajectory of patients
with a current depressive or anxiety disorder remain to be
conducted. This study examines whether various salivary
cortisol measures (cortisol awakening response, evening
level and suppression after dexamethasone ingestion) pre-
dict the 2-year course trajectory in 837 subjects with base-
line depression or anxiety disorders, correcting for detailed
demographic and clinical covariates.
2. Methods
2.1. Study sample
Data are from the Netherlands Study of Depression and
Anxiety (NESDA), a large cohort study on the course of
depressive and anxiety disorders among 2981 adults
(18—65 years). Respondents were recruited from the com-
munity, in primary care through a screening procedure con-
ducted among 65 general practitioners, and in specialized
mental health care when newly enrolled at one of the 17
participating mental health organization locations. The over-
all study sample included persons with psychopathology as
well as controls without a psychiatric diagnosis. General
exclusion criteria — determined through physicians’ records
as well as through screening questions to the respondents
during the screening phone interview — were: a primary
diagnosis of psychotic disorder, obsessive compulsive disor-
der, bipolar disorder, or severe addiction disorder and not
being fluent in Dutch. For objectives and methods of NESDA
see Penninx et al. (2008) The research protocol was approved
by the Ethical Committee of participating universities and all
respondents provided written informed consent.
Baseline data were obtained from September 2004 to
February 2007. After 2 years (October 2006 to April 2009),
a face-to-face follow-up assessment was conducted with a
response of 87.1% (2596 of the 2981 respondents partici-
pated). Non-response was significantly higher among those
with younger age, lower educational level, non-North Eur-
opean ancestry and those with major depressive disorder, but
was not associated with sex or the presence of anxiety
disorder (Lamers et al., 2012).
The presence of depressive (Major Depressive Disorder,
Dysthymia) or anxiety (Panic Disorder, Social Phobia,
Generalized Anxiety Disorder, Agoraphobia) disorders was
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ment (CIDI) according to DSM-IV criteria (American Psychia-
tric Association, 2001). For the present analysis, only
subjects who were symptomatic in the month before baseline
were included. Consequently, we restricted the sample to
the 1456 subjects with a 6-month depressive or anxiety
diagnosis who confirmed symptoms in the month prior to
baseline at either the CIDI recency questions or the Life Chart
Interview (see below). Of these 1456 subjects, 1185 (81.4%)
participated in the 2-year follow-up assessment (median
in-between time = 24 months) and had complete data on
outcome indicators. We subsequently excluded a total of
7 pregnant or breastfeeding women and 77 participants
on corticosteroids, leaving an initial sample of 1101
respondents.
Of these, 837 (76.0%) returned sufficient saliva samples to
contribute to at least one of the saliva cortisol analyses (1-h
awakening values, evening value or DST) and therefore con-
stitute the study sample. These 837 persons did not signifi-
cantly differ from the 264 respondents with missing cortisol
indicators in sex, or course outcome, but were older (42.8
versus 38.7 years, p < 0.001), more educated (12.0 versus
11.3 years, p = 0.005) and differed in baseline psychiatric
status (22.2% depression, 42.8% anxiety disorder and 35.0%
comorbidity versus 21.2% depression, 34.8% anxiety disorder
and 43.9% comorbidity, p = 0.02).
2.2. Course of depressive and anxiety disorders
As described elsewhere (Penninx et al., 2011), course of
depressive and anxiety disorders was determined using two
main sources of data collected during the 2-year follow-up
assessment: (1) the CIDI interview and the (2) Life Chart
Interview (LCI). The CIDI interview determined the presence
of DSM-IV classified depressive and anxiety disorders during
the time between baseline assessment and 2-year follow-up
assessment. Organic exclusion rules were used in defining
diagnoses, and hierarchy-free diagnoses were made to allow
for research into comorbidity. For all persons with detected
depressive or anxiety symptoms in the CIDI interview, the LCI
was completed. This assessment uses a calendar method to
determine life events during the 2-year follow-up period to
refresh memory, and then assessed separately the presence
of depressive and anxiety symptoms at each month during
this period (Lyketsos et al., 1994). In addition, for each month
with reported symptoms, the severity of symptoms was
assessed ranging from no or minimal, mild, moderate,
severe, or very severe symptoms. Symptoms on LCI were
only considered to be present when at least of mild severity.
Using both the CIDI and LCI data, distinction was made
between those with remission of symptoms — defined as
the occurrence of a time-point during follow-up at which
no symptoms of the index disorder was reported for three
consecutive months — versus those with a chronic course —
defined as no remission during the 2-year follow-up. For
instance, remission of an anxiety disorder was considered
present when no anxiety symptoms at all existed for three
consecutive months during follow-up, and likewise a comor-
bid condition was considered remitted when no symptoms at
all of both anxiety or depression existed for three consecu-
tive months. This three-month criterion is in line with that
used before (Spijker et al., 2002) and was uniformly appliedacross all disorders to allow comparison of outcomes. No
distinction was made between remission and recovery
because the data did not allow for such precision.
2.3. Salivary cortisol
As described in more detail elsewhere (Vreeburg et al.,
2009b), respondents were instructed to collect saliva sam-
ples at home on a regular (working) day shortly after the
interview at baseline. Instructions concerning saliva sampling
prohibited eating, drinking tea or coffee or brushing teeth
within 15 min before sampling. Furthermore, no dental work
24 h prior to sampling was allowed. Saliva samples were
obtained using Salivettes (Sarstedt, Germany) at seven time
points covering 1-h awakening cortisol levels, evening levels
and a dexamethasone suppression test. 1-h awakening corti-
sol includes four sampling points; at awakening (T1) and 30
(T2), 45 (T3) and 60 (T4) minutes later. The two evening
values were collected at 2200 h (T5) and 2300 h (T6). Dex-
amethasone suppression is measured by cortisol sampling the
next morning at awakening (T7) after ingestion of 0.5 mg
dexamethasone directly after the saliva sample at 2300 h
(T6). Respondents were instructed to write down the exact
sampling times and time of ingestion of dexamethasone, so
that non-compliance could be detected. Samples were stored
in refrigerators and returned by mail. After receipt, Saliv-
ettes were centrifuged at 2000  g for 10 min, aliquoted and
stored at 80 8C. Cortisol analysis was performed by com-
petitive electrochemiluminescence immunoassay (E170
Roche, Switzerland). The functional detection limit was
2.0 nmol/l and the intra- and inter-assay variability coeffi-
cients in the measuring range were less than 10%. Data
cleaning excluded values >2 SD above the mean.
One-hour awakening cortisol. We calculated the area
under the curve with respect to the increase (AUCi) and with
respect to the ground (AUCg) using Pruessner’s formulas
(Pruessner et al., 2003). The AUCg is an estimate of the total
cortisol secretion over the first hour after awakening,
whereas the AUCi is a measure of the dynamic of the cortisol
awakening response (CAR), more related to the sensitivity of
the system, emphasizing changes over time after awakening
(Schmidt-Reinwald et al., 1999; Edwards et al., 2001; Feke-
dulegn et al., 2007). If samples were collected outside of a
margin of five minutes around the time protocol, values were
assigned missing. All persons for whom all four morning
samples were available (n = 706) could be included in the
AUC analyses. In addition, we conducted Linear Mixed Models
(LMM) analyses (see Section 2.6) using all four morning saliva
samples, which keeps original values on all four data points,
can accommodate for incomplete cases, and takes correla-
tion between repeated measurements into account (Gueor-
guieva and Krystal, 2004). All persons with at least two valid
morning cortisol values (n = 793) could be included in LMM
analyses, thereby reducing the effects of missing values and
including more patients in the analyses.
Evening cortisol. Since cortisol levels at 22h00 and 23h00
were strongly correlated (Spearman’s r = 0.8, p < 0.01), we
used the mean of both cortisol levels. Data from 832 subjects
were available for evening cortisol analyses.
Dexamethasone suppression test (DST). This test provides
information on the negative feedback system of the HPA axis,
since dexamethasone reduces cortisol level by acting on the
Table 1 Baseline characteristics.
N = 837
Sociodemographics
% female 65.1
Age (mean in years, SD) 42.8 (12.3)
Educational level (mean in years, SD) 12.0 (3.3)
Health indicators
% smoking 37.5
% cardiovascular disease 6.6
Baseline diagnosis
% Depression only 22.2
% Anxiety disorder only 42.8
% Comorbid disorder 35.0
Age of onset (mean, SD) 21.1 (12.7)
Symptom duration (mean %, SD) 57.2 (35.7)
Depression severity (mean IDS, SD) 29.4 (11.8)
Fear score (mean, SD) 33.3 (19.7)
Sampling factors
Awakening time (mean, SD) 7h32 (1h15)
% working on sampling day 58.7
Salivary cortisol levels
One-hour awakening cortisola:
AUCg (mean in nmol/l/h, SD) 19.4 (7.2)
AUCi (mean in nmol/l/h, SD) 2.7 (6.5)
Mean evening level (mean in nmol/l, SD) 5.4 (3.3)
Dexamethasone suppression testa:
Cortisol suppression ratiob (mean, SD) 2.8 (1.7)
Abbreviations: SD, standard deviation; IDS, inventory of depres-
sive symptoms; AUCg/i, area under the curve with respect to the
ground/increase.
a N = 706 for AUCs, N = 832 for evening cortisol and N = 768 for
DST.
b Cortisol suppression ratio = cortisol T1/cortisol T7.
Cortisol levels and course of depression and anxiety 1497pituitary (Carroll et al., 1981). Of the 800 persons with T1 and
T7, 768 (96.0%) subjects had taken the 0.5 mg dexametha-
sone (indicated by self-report) and were available for the DST
analyses. We calculated a cortisol suppression ratio by divid-
ing the cortisol value at T1 by the value at T7 the next
morning.
2.4. Covariates
Sociodemographics (sex, age, years of education), sampling
factors (awakening time and work status on the sampling day)
and health indicators (smoking status (current versus no),
cardiovascular disease) with effects on salivary cortisol vari-
ables in our study (Vreeburg et al., 2009b) and possible
effects on the course of psychopathology were included as
covariates. All covariates were assessed at the baseline
measurement.
2.5. Clinical characteristics
Several clinical baseline characteristics were taken into
account, because they showed to be predictive of subsequent
2-year course of depression and/or anxiety disorders in the
NESDA study (Penninx et al., 2011). Severity of depressive
symptoms was measured with the 30-item Inventory of
Depressive Symptomatology (Rush et al., 1996). Severity of
anxiety symptoms was measured using the 15-item Fear
Questionnaire (Marks and Mathews, 1979). Information on
duration of symptoms prior to baseline was derived from the
Life Chart Interview (LCI) (Lyketsos et al., 1994) conducted at
baseline, which assessed the percent of time the patient
spent with depressive and/or anxiety symptoms in the 4 years
prior to baseline. Age of onset of the index disorder was
assessed in the CIDI interview, and earliest age was used for
those with comorbid disorders. Finally, baseline disorder
status was included (Anxiety disorder, Depression, Comorbid
disorders). In the NESDA study, we did not observe that
additional information on subtype of disorder (such as panic
disorder versus social phobia versus generalized anxiety dis-
order, or dysthymia versus major depressive disorder) was not
differentially associated with 2-year course outcomes, there-
fore, we did not include subtype as additional covariates
(Penninx et al., 2011).
2.6. Statistical analyses
The associations between salivary cortisol indicators
(AUCg, AUCi, evening cortisol and cortisol suppression
ratio) and 2-year course outcome (unfavorable course ver-
sus remission) were analyzed using multiple logistic regres-
sion analyses. In addition, random coefficient analysis of
the four morning cortisol levels was performed using LMM
analyses comparing morning cortisol levels between per-
sons with and without an unfavorable course. Two-year
outcome (unfavorable course yes/no), time point (1, 2,
3, 4) and all covariates were entered as fixed factors,
subjects were treated as a random effect and a random
intercept was estimated. To examine whether the course of
cortisol level after awakening was different for persons
with a unfavorable course versus remission, we added a
group by time interaction term.3. Results
Baseline characteristics are presented in Table 1. In our
sample, 65.1% were women and the mean age at baseline
was 42.8 years. 186 (22.2%) had a pure depressive disorder
(‘Dep’), 358 (42.8%) had a pure anxiety disorder (‘Anx’) and
293 (35.0%) had comorbid depressive and anxiety disorders
(‘Comorbid’) at baseline. 347 (41.5%) developed an unfavor-
able course compared to 490 (58.5%) persons with remission
during the 2 years of follow-up. 73.5% of respondents showed
an increase in cortisol in the first hour after awakening, with
a mean increase of 10.4 nmol/l (or 80.3%).Of the 837 per-
sons, 157 (18.8%) had dysthymia, 512 (61.2%) had a major
depressive disorder, 361 (43.1%) had social phobia, 224
(26.8%) had a panic disorder with agoraphobia, 115 (13.7)
had a panic disorder without agoraphobia, 104 (12.4%) had
agoraphobia without a panic disorder, and 222 (26.5%) had a
generalized anxiety disorder CIDI diagnosis in the past 6
months (not shown in Table) (Table 2).
Fully adjusted results illustrated that a lower AUCg as well
as a lower AUCi were associated with the risk of an unfavor-
able course (RR = 0.85, p = 0.06 and RR = 0.83, p = 0.03,
respectively), as confirmed by LMM results (direct effect:
F = 1.88, p = 0.17, interaction with time: F = 3.48, p = 0.02,
Fig. 1). Evening cortisol and cortisol suppression after
Table 2 The adjusted risk of having a 2-year chronic course across various salivary cortisol indicators.
2-Year chronic course
RR (95% CI) a p RR (95% CI) b p
AUCg (nmol/l/h) c 0.87 (0.74—1.02) 0.09 0.85 (0.71—1.01) 0.06
AUCi (nmol/l/h) c 0.89 (0.76—1.05) 0.16 0.83 (0.70—0.98) 0.03
Evening cortisol (nmol/l) c 1.06 (0.91—1.23) 0.47 1.05 (0.89—1.24) 0.56
Cortisol suppression ratio c 0.97 (0.84—1.12) 0.68 0.97 (0.83—1.14) 0.71
Abbreviations: RR, relative risk; CI, confidence interval; AUCg/i, area under the curve with respect to the ground/increase.
a Adjusted for sex, age, education, smoking, working, awakening time and cardiovascular disease.
b Additionally adjusted for IDS score, fear score, age of onset, symptom duration and type of baseline disorder (Dep, Anx, Comorbid).
c Relative risks for continuous measures are given per SD increase. AUCg: SD = 7.2; AUCi: SD = 6.5; evening cortisol: SD = 3.3, cortisol
suppression ratio: SD = 1.7.
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1498 S.A. Vreeburg et al.dexamethasone ingestion were not related to a 2-year unfa-
vorable course. When we tested for quadratic relations,
no p-values below 0.10 were obtained for all the quadratic
terms, indicating that no additional non-linear associations
could be confirmed.
To further graphically explore the relationship between
the AUCg and AUCi with an unfavorable course, we created
quintiles of these cortisol measures. Fig. 2 depicts the rela-
tionship between the cortisol awakening curve and the risk of
unfavorable course across quintiles. Where quintiles of the
AUCg were not significantly associated with the risk of unfa-
vorable course, the lowest quintile of the AUCi was asso-
ciated with an increased risk of unfavorable course as
compared to the middle quintile (Fig. 2). The quintiles did
not appear to be consistently associated with risk of unfavor-
able course, the risk was only increased for the lowest
quintile of AUCi (lowest quintile versus all higher quintiles
together: RR = 1.90, 95% CI = 1.24—2.90, p = 0.003).
Additional analyses were conducted on the association of
AUCi and unfavorable course to examine whether the found
association was consistent across disorders. We tested the
presence of an interaction between AUCi and baseline dis-
order status (Anx, Dep, Comorbid), but this was not signifi-
cant ( p > 0.6), suggesting that the finding appears to be12
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Figure 1 Baseline 1-h cortisol awakening levels for persons
with and without a chronic course after two years. Analyses are
adjusted for sex, age, education, smoking, working, awakening
time, cardiovascular disease, IDS score, Fear score, age of onset,
symptom duration and type of baseline disorder (Dep, Anx,
Comorbid). LMM results: direct effect: F = 1.88, p = 0.17, inter-
action with time: F = 3.48, p = 0.02. Per time-point: Awakening:
p = 0.48, 30 min: p = 0.07, 45 min: p = 0.08 and 60 min: p = 0.11.robust across baseline disorder groups. Although the receipt
of medication treatment at baseline was not associated with
course outcome in multivariable analyses (Penninx et al.,
2011) and only tricyclic antidepressant (TCA) use was asso-
ciated with baseline CAR levels (Vreeburg et al., 2009a), we
conducted additional analyses in which we adjusted for use of
TCAs, selective serotonin reuptake inhibitors and other anti-
depressants. These analyses indeed yielded similar results.1.72
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Figure 2 Quintiles of the cortisol awakening response (AUCg
and AUCi) and risk of chronic course. Analyses are adjusted for
sex, age, education, smoking, working, awakening time, cardio-
vascular disease, IDS score, Fear score, age of onset, symptom
duration and type of baseline disorder (Dep, Anx, Comorbid). P-
values compared to the middle quintile: AUCg: p = 0.81,
p = 0.64, p = 0.48 and p = 0.22, respectively, AUCi: p = 0.05,
p = 0.58, p = 0.92 and p = 0.50, respectively.
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et al., 2010) and childhood trauma exposure (Holleman
et al., 2012) in our study were not associated with HPA-axis
indicators. Consequently, we did not further conduct ana-
lyses with these additional covariates.
4. Discussion
The present study is the first to examine extensive salivary
cortisol measures and 2-year course of depressive and anxi-
ety disorders. Results indicate that a lower cortisol awaken-
ing response is associated with an increased risk of an
unfavorable, chronic course trajectory of depression and/
or anxiety disorders over 2 years. Evening cortisol and cortisol
suppression after dexamethasone ingestion were not asso-
ciated with 2-year course of depression and anxiety.
Most prior studies reported no relationship between base-
line HPA-axis indicators and treatment response or outcome
among patients with depression or panic disorder (Coryell
and Noyes, 1988; Ribeiro et al., 1993; Hatzinger et al., 2002;
Brouwer et al., 2006; Papakostas et al., 2010). However, none
of these studies, examining HPA-axis activity as predictor for
course outcome, included the CAR. We observed that a lower
CAR was associated with the risk of a chronic course, inde-
pendent of important covariates including important clinical
course predictors. The CAR showed to be unrelated to diurnal
cortisol rhythm and to be under genetic control, which is in
contrast to the other diurnal cortisol measures (Wust et al.,
2000; Edwards et al., 2001). The CAR is more than an index of
the HPA axis, since it is probably closely linked to the supra-
chiasmatic nucleus and there is evidence that the CAR can vary
in response to the anticipated demands of the upcoming day in
order to meet those demands, both physically and mentally
(Clow et al., 2010). There is increasing interest over the years
in the CAR as a promising biomarker because it represents a
distinct feature of the HPA axis and because it is easily
collected. An attenuated as well as an increased CAR have
been associated with adverse psychosocial factors and psy-
chopathology (e.g. Chida and Steptoe, 2009).
How can we explain our finding of a lower CAR to be
predictive of an unfavorable 2-year course? A low CAR is
potentially indicative of hypocortisolism. It has been
hypothesized that after long periods of (psychological or
physical) stress, the HPA axis becomes less responsive
through down-regulation of the receptors, resulting in low
cortisol levels (Heim et al., 2000; Fries et al., 2005). Results
supporting this theory come from studies in depressed older
persons where hypocortisolism in depression showed to be
associated with chronic and recurrent depressive episodes
(Bremmer et al., 2007) and physical frailty (Penninx et al.,
2007). In addition, Miller et al. (2007) conducted a meta-
analysis on chronic stress and HPA-axis activity and reported
that morning cortisol is especially lower when time has
passed since the occurrence of the stressor and the stressor
is no longer present, and when the stressor concerns an
uncontrollable threat to the physical self, or traumatic
stressor. However, these results were mainly based on
cross-sectional studies examining one morning cortisol sam-
ple. Therefore, longitudinal studies are warranted to exam-
ine the temporal associations between chronic stress and
HPA-axis activity, including the CAR.Down-regulation after chronic stress could also be
reflected in the CAR, since several studies have reported a
relationship between chronic or severe stress exposure and a
blunted CAR (Meinlschmidt and Heim, 2005; O’Connor et al.,
2009). Although the predictive effect of the CAR for the
course of depressive and anxiety disorders in our sample
was independent of symptom duration at baseline and child-
hood trauma, chronic stress exposure could be of impor-
tance, since we did not actually assess chronic stress and
only captured symptoms of the few years before baseline and
not lifetime exposure.
A possible mechanism for hypocortisolism is down-regula-
tion of corticotrophin-releasing-factor (CRH) receptors in the
pituitary, following a longer period of stress-induced
hypothalamic CRH secretion, resulting in lower adrenocorti-
cotropic hormone (ACTH) and reduced cortisol levels (Heim
et al., 2000). Alternatively, reduced biosynthesis or depletion
of CRH, ACTH and/or cortisol or increased sensitivity of the
HPA-axis to negative feedback (Heim et al., 2000; Fries et al.,
2005) could play a role in hypocortisolism. This latter
mechanism might be less important in explaining our find-
ings, since we did not observe an association between the
DST and an unfavorable course.
However, it is unclear whether these mechanisms also
apply to the CAR, since this is a distinct feature of HPA-axis
activity. It has been suggested that the CAR is under regu-
latory control of the hippocampus (Fries et al., 2009).
Although the hippocampus has an inhibitory effect on HPA-
axis activity in general, the integrity of the hippocampus
appears to be necessary for the CAR (Buchanan et al., 2004;
Pruessner et al., 2007; Fries et al., 2009). A reduced hippo-
campus found especially among the chronically depressed
(McKinnon et al., 2009) — has been associated with a blunted
CAR (Buchanan et al., 2004; Pruessner et al., 2007). There-
fore, the hippocampus might play an important role in
explaining our result. A reduced hippocampus may contribute
to a chronic course through a permanent vulnerability, pos-
sibly mediated by lower cortisol levels. However, longitudinal
studies are warranted to entangle the relationship between
hippocampus, HPA-axis activity and the onset and course of
depressive and anxiety disorders. Taken together, chronic
stress exposure may have lead to down-regulation of the
receptors of the HPA-axis system and reduction of hippocam-
pal volume, thereby resulting in a lower CAR. In addition,
depression is associated with inactivity or a lack of interest
and anxiety is associated with avoidance behavior. These
characteristics may lead to patient’s perceptions that there
is no reason to get active after awakening, which may make
the CAR superfluous. In support of this is that an increase of
behavioral activity in depressed people leads to a decrease of
symptoms (e.g. Lejuez et al., 2001) and affects hippocampal
neurogenesis (Nithianantharajah and Hannan, 2009).
These underlying mechanisms could explain why a lower
CAR was found to be associated with an unfavorable, chronic
course trajectory. Another explanation for our findings could
be that underlying chronic conditions are associated with a
low CAR which further determines poor course trajectory. For
instance, a blunted CAR has been observed in post-traumatic
stress disorder (Wessa et al., 2006) and chronic fatigue
syndrome (Roberts et al., 2004). Alternatively, these disor-
ders may share a common pathophysiology with chronic
depression.
1500 S.A. Vreeburg et al.We previously observed that a higher CAR was associated
with the presence of MDD and panic disorder with agorapho-
bia (Vreeburg et al., 2009a,b). In contrast, among current
patients it appeared to be a low CAR that was predictive of an
unfavorable course over time. Possibly, a higher cortisol
awakening curve is associated with the onset of depressive
disorder and/or panic disorder with agoraphobia and a lower
CAR with the unfavorable course of these disorders. The
observations that a higher cortisol awakening curve is asso-
ciated with parental history of depression or anxiety in
unaffected offspring (Mannie et al., 2007; Vreeburg et al.,
2010a) and with the incidence of depression in adolescents,
(Adam et al., 2010) support the idea that a higher cortisol
awakening curve is associated with the onset of depression.
Possibly, there are two distinct pathways: (1) a (genetic)
biological vulnerability of depressive or anxiety disorders via
high (morning) cortisol levels; and (2) a ‘scar’ effect as a
result of high allostatic load during life resulting in a lower
CAR and chronicity of depression. Future longitudinal studies
are warranted to entangle these pathways. Possibly, these
different pathways can explain some of the inconsistencies
reported in the previous literature on HPA-axis activity in
depressive and anxiety disorders.
Most previous studies reported no relationship between
basal HPA-axis indicators or the DST and outcome of depres-
sion (Coryell and Noyes, 1988; Ribeiro et al., 1993; Hatzinger
et al., 2002; Brouwer et al., 2006; Papakostas et al., 2010).
Although no studies specifically examined the development
of an unfavorable course over 2 years, previous results
appear to be in concordance with our negative findings with
evening cortisol and the DST. Possibly, the diurnal rhythm and
negative feedback system are not of importance in the
development of an unfavorable course. However, since asso-
ciations were present in e.g. panic disorder studies (Coryell
et al., 1991; Abelson and Curtis, 1996), it could be that in
specific subgroups these HPA-axis indicators are associated
with course trajectory.
Our study had several strengths, including a large repre-
sentative sample of outpatients who were longitudinally
examined for 2 years. In addition, we obtained several
salivary cortisol measures at baseline, and were able to
take several important covariates as well as clinical char-
acteristics into account. Also some limitations have to be
acknowledged. The effect we found was similar across
different types of baseline disorder (depression only, anxi-
ety disorder only and comorbid disorders), since interaction
terms were not significant. However, our subsamples of
specific depressive or anxiety disorders, such as social
phobia or GAD, were not sufficiently large to examine
the role of salivary cortisol measures in their course. In
our previous study, we observed that of the subtypes of
anxiety disorders only panic disorder with agoraphobia was
associated with higher cortisol values (Vreeburg et al.,
2010b). However, in Penninx et al. (2011) we reported that
subtype of anxiety disorder (panic versus social phobia
versus generalized anxiety disorder) was not differentially
associated with course trajectory. Therefore, it is unlikely
that in our sample, results would have been very different
if we would include subtypes as a specific covariate.
Restricted analyses on specific subgroups is also very diffi-
cult given the large comorbidity of depression and anxiety
disorders. Persons who provided saliva samples were older,more educated and less likely to have anxiety disorders or
comorbidity. The latter disorders had a higher risk of an
unfavorable course than depression only (Penninx et al.,
2011). Since we are looking at within-person associations
(baseline levels correlated with longitudinal course out-
come within a person), we do not believe a small sample
selection can impact on our overall results. In addition,
since we still have a substantial number of persons with
comorbidity in our sample (35.0%), we do not believe that
the generalizability of our results is very much affected.
Non-compliance with the sampling instructions could have
resulted in a measurement error and could have con-
founded our results. However, it should be noted that even
when closely monitoring awakening, still at least 15% of all
persons are not responding with a morning cortisol rise
(Dockray et al., 2008). Finally, salivary cortisol samples
were only measured on one day. Sampling on multiple days
could have increased the reliability of the measurements
(Hellhammer et al., 2007). However, the large sample size
of our study may have (partly) compensated for this.
To conclude, this study is the first to longitudinally exam-
ine the relationship between (salivary) cortisol measures and
an unfavorable course trajectory of depressive and/or anxi-
ety disorders. Findings further add to the importance of the
CAR in mental health, since we found a lower CAR among
depression and anxiety patients to be predictive of an unfa-
vorable course over two years.
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